TCGA-A8-A09M-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 34
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.460
- UNFOLDED_PROTEIN_RESPONSE+0.370
- DNA_REPAIR+0.360
- OXIDATIVE_PHOSPHORYLATION+0.310
- ALLOGRAFT_REJECTION+0.290
- MYC_TARGETS_V1+0.290
- PEROXISOME+0.280
- E2F_TARGETS+0.240
- MYC_TARGETS_V2+0.240
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.520
- NOTCH_SIGNALING-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- TGF_BETA_SIGNALING-0.420
- UV_RESPONSE_DN-0.390
- ANGIOGENESIS-0.360
- HYPOXIA-0.350
- MYOGENESIS-0.340
- WNT_BETA_CATENIN_SIGNALING-0.330
- APICAL_JUNCTION-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A0TV-01A-21R-A084-07 | — | B | 0.885 |
| 2 | MNG171 | — | — | 0.853 |
| 3 | TCGA-A8-A06T-01A-11R-A00Z-07 | — | B | 0.841 |
| 4 | SRR26320066 | — | — | 0.839 |
| 5 | TCGA-A8-A06U-01A-11R-A00Z-07 | — | B | 0.837 |
| 6 | TCGA-55-1596-01A-01R-0946-07 | — | cohortA4 | 0.836 |
| 7 | TCGA-C8-A12U-01A-11R-A115-07 | — | B | 0.834 |
| 8 | TCGA-KU-A6H7-01A-11R-A31N-07 | — | — | 0.832 |
| 9 | TCGA-D8-A1X6-01A-11R-A14M-07 | — | B | 0.831 |
| 10 | 20080227.Her2HRpos | — | C | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.370 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.290 | Inavolisib | — uncovered |
| PEROXISOME | 0.280 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.240 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.110 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.110 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |